Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.49 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810651 | 1.00 | POLG (0.54) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL20906737 | 1.00 | POLG (0.54) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL22300298 | 1.00 | POLG (0.54) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL15201233 | 1.00 | POLG (0.54) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL2926533 | 0.98 | POLB (0.55) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL14660974 | 0.98 | POLB (0.55) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL15472378 | 0.94 | P2RY2 (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Triphosphate SCHEMBL28135309 | 0.91 | DNMT1 (0.58) | POLGPOLBDNMT1DNMT3B | |
| SCHEMBL1331043 | 0.90 | TYMS (0.55) | POLBDNMT1DNMT3B | |
| SCHEMBL336318 | 0.90 | TYMS (0.55) | POLBDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | TETRAGON BIOSCIENCE LTD. (IL) | 2026-04-21 | — | — | US | claimed |
| EP-4591940-A2 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2025-07-30 | — | — | EP | claimed |
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | claimed |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2024-07-04 | — | — | US | claimed |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | HEMISPHERIAN AS (NO) | 2024-04-23 | — | — | US | claimed |
| CN-113543789-B | Deoxycytidine or uridine derivatives for use in cancer treatment | 赫米斯弗连有限公司 | 2024-04-05 | — | — | CN | claimed |
| EP-4233879-A1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2023-08-30 | — | — | EP | claimed |
| EP-3917538-B1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2023-07-12 | — | — | EP | claimed |
| US-20220117992-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2022-04-21 | — | — | US | claimed |
| EP-3917538-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2021-12-08 | — | — | EP | claimed |
| WO-2020157335-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2020-08-06 | — | — | WO | claimed |
| CN-104592334-A | Method for synthesizing tetrasodium 5-hydroxymethyl and 5-aldehyde-2'-deoxycytidine triphosphate | UNIV JIANGXI NORMAL SCI & TECH | 2015-05-06 | — | — | CN | claimed |
| EP-0804446-B1 | METHOD AND COMPOSITION FOR STABILIZATION OF LABELLED NUCLEOSIDE TRIPHOSPHATES | PHARMACIA BIOTECH INC (US) | 2003-07-09 | — | — | EP | claimed |
| WO-2026102094-A1 | COMBINED CHEMISTRY AND COMPUTATIONAL CORRECTIONS FOR METHYL-BIAS | FOUNDATION MEDICINE, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125749-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | TETRAGON BIOSCIENCE LTD. (IL) | 2026-04-21 | — | — | US | disclosed |
| EP-0286898-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| EP-0285950-A2 | A drug delivery conjugate | ENZO BIOCHEM, INC. (US) | 1988-10-12 | — | — | EP | disclosed |
| EP-0285058-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0097373-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1984-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117992-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | UMPS, UPP1, TYMP | POLG 464/4885POLB 272/4885P2RY2 525/4885 |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | UMPS, UPP1, TYMP | POLG 464/4885POLB 272/4885P2RY2 525/4885 |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | UMPS, UPP1, TYMP | POLG 444/4885POLB 261/4885P2RY2 552/4885 |
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | CDA, DCTD, RNMT | POLG 354/4885POLB 57/4885P2RY2 203/4885 |
| US-20260125749-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | POLRMT, PITPNB, NUP205 | POLG 528/4885POLB 81/4885P2RY2 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.